Karyopharm Therapeutics Inc (KPTI) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.88 (+5.03%), Market cap $0.20B, 52-week low–high $3.77 ~ $10.09.
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult
Financial statements, price targets, institutional (13F) holdings and related news for Karyopharm Therapeutics Inc are updated in real time on BlackAll Trade.
Karyopharm Therapeutics Inc trades at $1.88 (+5.03%). Real-time quotes and charts are available on BlackAll Trade.
Karyopharm Therapeutics Inc has a market cap of about $0.20B.
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in